Xaira Therapeutics launched with a historic $1 billion investment, aimed at leveraging artificial intelligence for drug discovery and development, particularly emphasizing generative AI. This move reflects a growing interest in harnessing AI’s capabilities within the biopharma industry. Generative AI, capable of producing novel ideas and content, gained traction following the release of ChatGPT in November 2022. Companies like Moderna are expanding collaborations with AI developers like OpenAI to integrate generative AI into their operations. Others are partnering with AI services firms or developing their own generative AI technology in-house. This trend signals a significant shift in how biopharma approaches innovation and underscores the industry’s recognition of AI’s potential.